Walleye Capital LLC Adverum Biotechnologies, Inc. Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Mar 03, 2022	SELL	$1.74 - $2.4 $45,556 - $62,836	-26,182 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.08 - $3.6 $432,646 - $748,810	-208,003 Reduced 88.82%	26,182 $57,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $786,861 - $2.47 Million	234,185 New	234,185 $820,000
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $795,760 - $1.15 Million	-80,870 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $832,961 - $1.75 Million	80,870 New	80,870 $833,000
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $872,381 - $1.78 Million	-109,321 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $407,147 - $971,746	79,521 Added 266.85%	109,321 $1.26 Million
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $156,152 - $473,522	29,800 New	29,800 $163,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.